المؤلفون: Hearn JWD; Department of Radiation Oncology, University of Michigan, Ann Arbor., Sweeney CJ; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Almassi N; GU Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.; Memorial Sloan Kettering Cancer Center, New York, New York., Reichard CA; GU Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.; University of Texas MD Anderson Cancer Center, Houston., Reddy CA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.; Cancer Biostatistics Section, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Li H; Cancer Biostatistics Section, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Hobbs B; Cancer Biostatistics Section, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Jarrard DF; Department of Medical Oncology, University of Wisconsin Hospital and Clinics, Madison., Chen YH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dreicer R; University of Virginia Cancer Center, Charlottesville., Garcia JA; Taussig Cancer Institute, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio., Carducci MA; Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, Maryland., DiPaola RS; Department of Medical Oncology, University of Kentucky, Lexington., Sharifi N; GU Malignancies Research Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.; Taussig Cancer Institute, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio.

المصدر: JAMA oncology [JAMA Oncol] 2020 Apr 01; Vol. 6 (4), pp. e196496. Date of Electronic Publication: 2020 Apr 09.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Docetaxel/*administration & dosage , Multienzyme Complexes/*genetics , Progesterone Reductase/*genetics , Prostatic Neoplasms, Castration-Resistant/*drug therapy , Prostatic Neoplasms, Castration-Resistant/*surgery , Steroid Isomerases/*genetics, Aged ; Alleles ; Androgen Antagonists/administration & dosage ; Disease Progression ; Disease-Free Survival ; Genotype ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Treatment Outcome

المؤلفون: Autio KA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York., Dreicer R; Department of Medicine and Urology, University of Virginia School of Medicine, Charlottesville., Anderson J; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Garcia JA; Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio., Alva A; Division of Hematology and Oncology, Department of Medicine, University of Michigan Health System, Ann Arbor., Hart LL; Florida Cancer Specialists, Fort Myers., Milowsky MI; Division of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill., Posadas EM; Division of Hematology and Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California., Ryan CJ; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco., Graf RP; Epic Sciences, Inc, San Diego, California., Dittamore R; Epic Sciences, Inc, San Diego, California., Schreiber NA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Summa JM; Bind Therapeutics, Inc, Cambridge, Massachusetts., Youssoufian H; Bind Therapeutics, Inc, Cambridge, Massachusetts., Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York., Scher HI; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medicine, New York, New York.

المصدر: JAMA oncology [JAMA Oncol] 2018 Oct 01; Vol. 4 (10), pp. 1344-1351.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Docetaxel/*therapeutic use , Nanoparticles/*therapeutic use , Prostate-Specific Antigen/*antagonists & inhibitors , Prostatic Neoplasms, Castration-Resistant/*drug therapy, Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Diarrhea/chemically induced ; Disease-Free Survival ; Docetaxel/adverse effects ; Fatigue/chemically induced ; Humans ; Male ; Middle Aged ; Nanoparticles/adverse effects ; Nausea/chemically induced ; Neoplasm Metastasis ; Prostate-Specific Antigen/metabolism ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Treatment Outcome

المؤلفون: Bertrand Tombal, Ping Lin, Joyce Steinberg, Tomasz M. Beer, Jennifer Sugg, Johann S. de Bono, Cora N. Sternberg, Mohammed Al-Adhami, Teresa Parli, Howard I. Scher, Andrew J. Armstrong

المساهمون: UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie

المصدر: JAMA Oncology, Vol. 6, no. 2, p. 217-225 (2020)

مصطلحات موضوعية: Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Bone Neoplasms, Docetaxel, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Nitriles, Phenylthiohydantoin, medicine, Enzalutamide, Humans, Clinical significance, 030212 general & internal medicine, Pseudoprogression, Aged, Aged, 80 and over, business.industry, Hazard ratio, Bone metastasis, Middle Aged, medicine.disease, Discontinuation, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Benzamides, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7cc84cd2a653ec2f3db41ae36880530
https://pubmed.ncbi.nlm.nih.gov/31830203

المؤلفون: Hordijk, Sophie, Vogelzang, NJ, Petrylak, DP, Budnik, N, Wiechno, PJ, Sternberg, CN, Doner, K, Bellmunt, J, Burke, JM, de Olza, MO, Choudhury, A, Gschwend, JE, Kopyltsov, E, Flechon, A, Van As, N, Houede, N, Barton, D, Fandi, A, Jungnelius, U, Li, SY, Li, JS, Li, SS, de Wit, Ronald

المساهمون: Medical Oncology

المصدر: JAMA Oncology, 3(1), 68-75. American Medical Association

مصطلحات موضوعية: Oncology, Male, Cancer Research, Journal Club, medicine.medical_treatment, Phases of clinical research, Docetaxel, Kaplan-Meier Estimate, urologic and male genital diseases, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Lenalidomide, Aged, 80 and over, education.field_of_study, Hazard ratio, Middle Aged, 3. Good health, Thalidomide, Prostatic Neoplasms, Castration-Resistant, 030220 oncology & carcinogenesis, Taxoids, therapeutics, medicine.drug, Adult, medicine.medical_specialty, Population, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Post-hoc analysis, medicine, Humans, education, neoplasms, Aged, Chemotherapy, business.industry, organic chemicals, medicine.disease, Surgery, Prednisone, business, Progressive disease

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afc958ed3a831634f29ffdf32f7ef67
https://pubmed.ncbi.nlm.nih.gov/28278075

المؤلفون: Emmanuel S. Antonarakis, Mary Nakazawa, Rosa Nadal, Channing J. Paller, Mario A. Eisenberger, Samuel R. Denmeade, Yan Chen, Brandon Luber, Hao Wang, Jun Luo, Changxue Lu, Michael A. Carducci

المصدر: JAMA Oncology. 1:582

مصطلحات موضوعية: Male, Oncology, Cancer Research, Time Factors, Journal Club, Docetaxel, Kaplan-Meier Estimate, chemistry.chemical_compound, Prostate cancer, Circulating tumor cell, Risk Factors, Protein Isoforms, Prospective Studies, Aged, 80 and over, Academic Medical Centers, Middle Aged, Neoplastic Cells, Circulating, Chemotherapy regimen, Prostatic Neoplasms, Castration-Resistant, Phenotype, Treatment Outcome, Receptors, Androgen, Cabazitaxel, Benzamides, Androstenes, Kallikreins, Taxoids, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Adenocarcinoma, Disease-Free Survival, Article, Predictive Value of Tests, Internal medicine, Nitriles, Phenylthiohydantoin, Biomarkers, Tumor, medicine, Humans, Enzalutamide, Genetic Predisposition to Disease, RNA, Messenger, Progression-free survival, Aged, Taxane, business.industry, Patient Selection, Prostate-Specific Antigen, medicine.disease, chemistry, Drug Resistance, Neoplasm, Baltimore, business, Biomarkers

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d536f468f45fe7729be06b5abbaad663
https://doi.org/10.1001/jamaoncol.2015.1341